NCT02689336 2019-09-09Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid TumorsWashington University School of MedicinePhase 2 Withdrawn
NCT00831844 2015-03-30Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 2 Completed116 enrolled 8 charts